Effective January 1, 2023, out-of-pocket costs for insulin are capped at $35 per monthly prescription among Medicare Part D enrollees under the Inflation Reduction Act (IRA). A similar cap takes effect in Medicare Part B on July 1, 2023.
Displaying 1 - 2 of 2. 10 per page. Page 1.Advanced Search
ASPE Data Point
Insulin Affordability and the Inflation Reduction Act: Medicare Beneficiary Savings by State and Demographics
January 24, 2023
Report to Congress
Report to Congress on the Affordability of Insulin
December 16, 2022
This Report to Congress examines the critical role that insulin plays in the treatment of diabetes, reviews evidence on how insulin affordability affects adherence to insulin treatment and affects downstream health consequences, and describes policy efforts to improve the affordability of insulin.